Evaluation of a Blood Test for Detecting 10 Types of Cancer Significantly Progresses

In a significant stride towards early cancer detection, the multi-site UK clinical study named MODERNISED is making progress. The study, run by University of Southampton researchers in partnership with the Southampton Clinical Trials Unit (SCTU) and Proteotype Diagnostics Ltd, is evaluating a blood test called ENLIGHTEN.

The innovative ENLIGHTEN blood test, developed by Proteotype Diagnostics Ltd, is a first-of-its-kind test designed to detect signals of up to 10 cancers at their earliest, treatable stages. This development, if successful, could revolutionise cancer diagnostics and improve early detection rates.

The study has already enrolled over 450 participants, with recruitment aiming to continue. The goal is to include 1,000 newly diagnosed NHS cancer patients and 350 symptomatic and healthy volunteers from five hospitals across the country.

The need for early detection is underscored by the experiences of individuals like Ian Robinson and Ian Dickerson. Mr. Robinson, a study participant from North Baddesley in Hampshire, was diagnosed with colorectal cancer despite showing no symptoms, emphasising the importance of early detection. Mr. Dickerson, another participant, underlines the importance of early diagnosis, stating that it allowed him to avoid chemotherapy and radiotherapy, leading to a good quality of life post-treatment.

The quoted individual, who has had two apparently fairly rare cancers, echoes the benefits of early diagnosis. They emphasise that cancer can happen to anyone and express support for the study's goals, although they are not specified as a participant in the MODERNISED study.

Funding for the study comes from the Office for Life Sciences, the Department of Health and Social Care, the Department for Science, Innovation and Technology, and the National Institute For Health and Care Research (NIHR) i4i programme.

Proteotype Diagnostics Ltd, the company developing the ENLIGHTEN blood test, is not explicitly mentioned as a partner in the MODERNISED study. However, the company is a pioneering diagnostics company focused on developing advanced multi-cancer early detection and personalised medicine tests.

The study aims to develop tests that could flag multiple cancers in one appointment, a significant step towards streamlining the diagnostic process and potentially saving lives. The press release does not provide new information about the MODERNISED study's recruitment status, aim, or findings. Preliminary studies suggest that ENLIGHTEN can accurately detect very early cancers, offering hope for early and effective treatment.

In conclusion, the MODERNISED study represents a significant step forward in the fight against cancer. With its focus on early detection and multi-cancer testing, it has the potential to revolutionise the way cancer is diagnosed and treated in the UK.

Evaluation of a Blood Test for Detecting 10 Types of Cancer Significantly Progresses